BRPI0917656A2 - Fatores viii e ix humanos produzidos de forma recombinante - Google Patents

Fatores viii e ix humanos produzidos de forma recombinante

Info

Publication number
BRPI0917656A2
BRPI0917656A2 BRPI0917656A BRPI0917656A BRPI0917656A2 BR PI0917656 A2 BRPI0917656 A2 BR PI0917656A2 BR PI0917656 A BRPI0917656 A BR PI0917656A BR PI0917656 A BRPI0917656 A BR PI0917656A BR PI0917656 A2 BRPI0917656 A2 BR PI0917656A2
Authority
BR
Brazil
Prior art keywords
recombinantly produced
human factors
produced human
factors viii
protein
Prior art date
Application number
BRPI0917656A
Other languages
English (en)
Inventor
Sandberg Helena
Stenlund Peter
Schröder Carola
Casademunt Elisabeth
Tiemeyer Maya
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of BRPI0917656A2 publication Critical patent/BRPI0917656A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROTEÍNA DO FATOR VIII OU IX HUMANO RECOMBINANTE, BEM COMO COMPOSIÇÃO FARMACÊUTICA, COMPLEXO E USO DA MESMA. A presente invenção refere-se a uma proteína do fator VIII ou IX humano recombinante que possui um padrão de glicosilação humano, porém a proteína é desprovida de ácido N-glicolilneuramínico e/ou do grupo de carboidrato Gal(Alfa)-3Gal.
BRPI0917656A 2008-08-21 2009-08-21 Fatores viii e ix humanos produzidos de forma recombinante BRPI0917656A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13625008P 2008-08-21 2008-08-21
EP08162765 2008-08-21
PCT/EP2009/060829 WO2010020690A1 (en) 2008-08-21 2009-08-21 Recombinantly produced human factor viii and ix

Publications (1)

Publication Number Publication Date
BRPI0917656A2 true BRPI0917656A2 (pt) 2017-07-11

Family

ID=40317066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917656A BRPI0917656A2 (pt) 2008-08-21 2009-08-21 Fatores viii e ix humanos produzidos de forma recombinante

Country Status (13)

Country Link
US (1) US9120873B2 (pt)
EP (1) EP2331569A1 (pt)
JP (1) JP2012500250A (pt)
KR (1) KR101921698B1 (pt)
CN (1) CN102119172A (pt)
AU (1) AU2009284113B2 (pt)
BR (1) BRPI0917656A2 (pt)
CA (1) CA2732423A1 (pt)
IL (1) IL210852A (pt)
MX (1) MX2011001624A (pt)
RU (1) RU2011110459A (pt)
WO (1) WO2010020690A1 (pt)
ZA (1) ZA201102020B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2321352T1 (sl) 2008-07-18 2016-04-29 Bristol-Myers Squibb Company Sestavki monovalentni za CD28 vezavo in metode uporabe
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2011131720A1 (en) 2010-04-20 2011-10-27 Octapharma Ag New stabilizing agent for pharmaceutical proteins
UA115120C2 (uk) * 2010-07-09 2017-09-25 Байоджен Хемофіліа Інк. Спосіб застосування химерного поліпептиду фактора ix
EP3626737B1 (en) 2011-05-13 2023-11-29 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
DK3360895T3 (da) 2014-06-06 2021-11-15 Octapharma Ag Præparat omfattende faktor-viii og von-willebrand-faktor-peptider

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
GB9010742D0 (en) 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
US5316680A (en) 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AUPO871997A0 (en) 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1154796B1 (en) 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
EP1224312A1 (en) * 1999-10-12 2002-07-24 The University of North Carolina at Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
AU5471501A (en) 2000-03-22 2001-10-03 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
EP1136553A1 (en) 2000-03-22 2001-09-26 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
EP3127916A1 (en) 2004-06-07 2017-02-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
US7365310B2 (en) 2005-06-27 2008-04-29 Agilent Technologies, Inc. Increased depth of field for high resolution imaging for a matrix-based ion source
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
KR20080033439A (ko) 2005-08-04 2008-04-16 넥타르 테라퓨틱스 에이엘, 코포레이션 Ｇ-ｃｓｆ 부분 및 중합체의 컨주게이트
SG162834A1 (en) 2006-07-14 2010-07-29 Genentech Inc Refolding of recombinant proteins
US20080207487A1 (en) 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US20080214462A1 (en) * 2007-02-01 2008-09-04 Baxter International Inc. FIX-Mutant Proteins for Hemophilia B Treatment
KR101293504B1 (ko) 2007-07-11 2013-08-07 노보 노르디스크 에이/에스 혼합형 또는 다중형 수지를 사용하는 인자 ｖⅰⅰⅰ의 정제
EP2220108A2 (en) 2007-11-15 2010-08-25 Novo Nordisk A/S Protein purification and endotoxin removal
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN101260145B (zh) 2008-04-11 2012-08-08 天津溥瀛生物技术有限公司 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺
DK2300497T3 (da) 2008-06-24 2012-10-29 Octapharma Ag Fremgangsmåde til oprensning af koagulationsfaktor VIII
CN102164943A (zh) 2008-09-24 2011-08-24 稳定技术有限公司 使用糖和聚乙烯亚胺保存多肽的方法

Also Published As

Publication number Publication date
CN102119172A (zh) 2011-07-06
US9120873B2 (en) 2015-09-01
WO2010020690A1 (en) 2010-02-25
KR20110057131A (ko) 2011-05-31
KR101921698B1 (ko) 2018-11-26
RU2011110459A (ru) 2012-09-27
IL210852A (en) 2014-06-30
AU2009284113A1 (en) 2010-02-25
EP2331569A1 (en) 2011-06-15
IL210852A0 (en) 2011-04-28
US20110262424A1 (en) 2011-10-27
AU2009284113B2 (en) 2015-05-14
JP2012500250A (ja) 2012-01-05
MX2011001624A (es) 2011-03-28
CA2732423A1 (en) 2010-02-25
ZA201102020B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
LTPA2017018I1 (lt) Rekombinantinis FSH, įskaitant alfa 2,3- ir alfa 2,6-sialilinimą
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
ES2559007T3 (es) Alfa1 antitripsina humana recombinante
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
ECSP11011367A (es) Composición farmacéutica
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
BRPI1006825A2 (pt) compostos pró-neurogênicos
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BR112012007563A2 (pt) peptídeos sintéticos antagonistas de miostatina
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
BRPI1007350B8 (pt) compostos espiro heterocíclicos bicíclicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL